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Abstract 
Several novel 6-thio-3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-based com-
pounds containing an ω-(dialkylamino(heterocyclyl)]alkyl fragment were synthe-
sized to examine their anticancer activity. Some of the 6-{[ω-(hetero-
cyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones (3.1–3.10) were 
obtained by the nucleophilic substitution of 6-[ω-halogenalkyl]thio-3-R-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-ones  (2.1–2.8) with azaheterocycles. Alter-
natively, compounds 3.1–3.22 were synthesized by alkylation of 3-R-6-thio-2Н-
[1,2,4]triazino[2,3-c]quinazoline-2-ones potassium salts (1.1–1.4) with (2-chloro-
ethyl)-N,N-dialkylamine  hydrochlorides  or 1-(2-chloroethyl)heterocycle  hydro-
chlorides. The structures of compounds were elucidated by 
1H, 
13C NMR,   
LC–MS and EI-MS analysis. Then anticancer and antibacterial, biolumi-
nescence inhibition of  Photobacterium leiognathi  Sh1 activities of the sub-
stances were tested in vitro. It was found that compound 3.18 possessed a wide 
range of anticancer activity against 27 cell lines of cancer: non-small cell lung, 
сolon, CNS, ovarian, renal, prostate, breast, melanoma and leukemia (log GI50 38  G. G. Berest et al.:   
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<  −5.65). The “structure-activity” relationship was discussed. COMPARE 
analysis for synthesized anticancer active compounds was performed. 
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Introduction 
The quinazoline skeleton is a heterocyclic system that can be found in many prospective 
anticancer drugs [1–17]. Some derivatives, notably 4-R-phenylaminoquinazolines (drugs 
«Iressa» (I), «Erlotinib» (II), «Vandetanib» (III) and others) are ATP-competitive 
irreversible inhibitors of the tyrosine-kinase epidermal growth factor receptor and others 
protein-kinase enzymes, which are widely used in oncological practice (Scheme 1) [3, 5]. 
It’s important that anticancer activity of 4-R-phenylaminoquinazolines is determined by 
both the base heterocycle and aniline fragment in 4
th position of molecule and requires the 
presence of halogens, hydroxy and cyano  group. To improve the pharmacokinetic 
properties, notably bioavailability and lipophilicity, it is advisable to introduce appropriate 
functional groups in 6
th and 7
th position of molecule. Such anintroduction of acryl- or butyn-
2-amide fragments leads to the increase of metabolism and elimination and decrease of 
accumulation, while methoxy-  and heterocyclylalkyloxy-groups are necessary for the 
improvement of hydrophobic interaction with the appropriate enzymes. 
The variants of annelation or introduction of different heterocyclic pharmacophores to 
quinazoline  skeleton were  described recently. [18–21].  Thus, [1,2,4]triazino[2,3-c]quin-
azoline (IV) is a product of annelation of quinazoline to triazine system, and from the view 
of medicinal chemistry optimization is undoubtedly an optimal target for anticancer drugs 
design. So, it is possible to modify the above mentioned molecule at the 3rd position of 
triazine system, the 6th position of pyrimidine, and the 8th-11th positions of benzene ring. 
In previous work we’ve made an attempt to modify structure (IV) at the 3rd (V) and 6th (VI, 
VII) positions [18–22]. Hence, 3-R-6-thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-
2-one (VI) is a promising “lead-compound” to combine with dialkylamino(heterocyclyl)alkyl 
substituent for development of the potent chemotherapeutic agents. 
Results and discussion 
Chemistry 
The known synthetic methods of  ω-dialkylamino(heteryl)alkylthioheterocyclic fragment 
formation are based on two main approaches: the first approach is the interaction of 
ω-halogenalkylthioheteryles with the excess of secondary amines in anhydrous medium, 
and the second approach is the  direct  alkylation  of  heterylthiones  by  ω-dialkylamino-
alkylhalogenes or 1-(ω-halogenoalkyl)heterocyclyles in organic solvents with the presence 
of organic or inorganic base. 
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Sch. 1.   Structures of quinazoline-based compounds and their medicinal chemistry 
optimization. 
Alkylation of substances 1.1–1.4 by symmetrical and asymmetrical dihalogenalkanes was 
investigated to fulfill  the first approach. According to the LC-MS data, refluxing the 
substances 1.1–1.2 with 1,2-dibromoethane for 10–20 min in water-alcohol solution led to 
the mixture of substances 2.1, 2.2 (up to 90%) with appropriate bisderivatives (4-8%) and 
starting substances (up to 2-6%). The treatment of compounds 1.3–1.4 with asymmetrical 
dihalogenalkanes under mentioned conditions yielded 90% of substances 2.1–2.8. When 
synthesis proceeded longer (up to 60 min) in anhydrous environment (propanol-2, 
dioxane), that led to less of a yield  (up to 60%) with an  increase  in  the amount of 
bisderivatives (up  to 20-40%).  The latter effect was caused by the low solubility of 
potassium salts 1.1–1.4 in anhydrous solvents. It’s important that substances 2.1–2.8 were 
easily purified by recrystallisation from ethanol or propan-2-ol. 
Refluxing of the 6-[ω-halogenalkyl]thio-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones 
(2.1–2.8) with the proper equimolar amount of heterocycles (pyrrolidine, piperidine, 
morpholine) in dioxane with potassium iodide, further neutralizing the obtained hydro-40  G. G. Berest et al.:   
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chlorides by sodium hydrocarbonate and extraction of substances with chloroform effected 
the lessening of yields (10–20%) of compounds 3.1–3.10 (Scheme 2). Products were quite 
easily and strongly oxidized in such conditions (reaction mixture became dark brown) that 
had a substantial influence on the purity of compounds 3.1–3.10. Replacement of solvent 
by ethanol or propan-2-ol and prolongation of reaction didn’t influence the increasing of 
substances yields. It was found that the product’s yields and purity could be improved by 
the addition of the excess  heterocycles  and refluxing in propan-2-ol–water mixture. 
Additionally, the obtained amines 3.1–3.10 could be easily extracted from reaction mixture 
with diethyl ether or chloroform after poured into water. 
1.1 R = CH3; 1.2 R= Ph; 1.3 R = 4-CH3Ph; 1.4 R = 4-CH3OPh; 2.1 R = CH3, n = 2, Hal = Br; 
2.2 R = Ph, n = 2, Hal = Br; 2.3 R = CH3, n = 3, Hal = Cl; 2.4 R = Ph, n = 3, Hal = Cl; 
2.5 R = 4-CH3Ph, n = 3, Hal = Cl; 2.6 R = 4-CH3OPh, n = 3, Hal = Cl; 2.7 R = CH3, n = 4, Hal = Cl; 
2.8 R = Ph, n = 4, Hal = Cl; 3.1 R = Ph, n = 2, z = 0, X = C; 3.2 R = Ph, n = 2, z = 1, X = C; 
3.3 R = Ph, n = 2, z = 1, X = O; 3.4 R = Ph, n = 3, z = 0, X = C; 3.5 R = Ph, n = 3, z = 1, X = C;  
3.6 R = Ph, n = 3, z = 1, X = O;3.7 R = CH3, n = 4, z = 1, X = C; 3.8 R = Ph, n = 4, z = 1, X = C;  
3.9 R = CH3, n = 4, z = 1, X = O; 3.10 R = Ph, n = 4, z = 1, X = O 
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Sch. 2.   Structures of quinazoline-based compounds and their medicinal chemistry 
optimization. 
The 3-R-6-thio-6,7dihydro-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones (1.1–1.4) potassium 
salts were alkylated with (2-chloroethyl)-N,N-dialkylamines hydrochlorides or 1-(2-chloro-
ethyl)heterocycles  hydrochlorides  in the presence of triethylamine to fulfill the second 
approach (Scheme 3). The water–propan-2-ol reaction medium provided the higher yields 
of resulting products 3.1–3.3, 3.11–3.22. 
The individuality and structure of synthesized substances were conﬁrmed by their IR, 
1H, 
13C NMR, and EI-MS data. In IR spectra the triazinoquinazoline system was characterized 
by: νС=О (1759–1658 сm
−1), νC-C (1520сm
−1 and 1449 сm
−1), νCS (713–604 сm
−1), νCS and 
νCN (1593–710 сm
−1) and δCH (902–649 сm
−1). The symmetric and asymmetric stretchings 
of СН2- moiety of compounds 2.1–2.8, 3.1–3.22 were detected at 2998-2800 cm
−1 and 
deformation  vibrations  −  at  1496–1470 cm
−1. Additionally long-chain alkanes (2.3–2.8, 
3.4–3.10) were characterized by vibrations at 769–760 cm
−1. Stretching vibration of νC-Br 
was characteristic for substances 2.1,  2.2, and for substances 2.3–2.8  –  νC-Сl  at  
750–700 сm
−1. С-N group of alkylamines chain was confirmed by stretching vibrations at 
1395–1001 cm
−1 and vibrations of N-Н group appeared at 3070–3055 cm
−1 and 1662–
1608 cm
−1 appropriate.   Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline… 41 
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Sch. 3.   Synthesis of the 6-{[2-(heterocyclyl)ethyl]thio}-3-R-2H-[1,2,4]triazino[2,3-
c]quinazoline-2-one (3.1–3.3) and 6-{[2-(dialkylamino)ethyl]thio}-3-R-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-ones (3.11–3.22). 
LC-MS spectra of substances 2, 3 were characterized by positive ions [M+1] and [M+3]. 
The latter ones characterized the presence of a sulfur isotope. Furthermore, LC-MS 
spectra of substances 2.3–2.8  had  an  additional  signal  caused  by  ion  [М+2],  which 
confirmed the presence of a chlorine atom in the molecule.  
In 
1H NMR spectra of 2.1–2.8, 3.1–3.22 triazinoquinazoline fragment was characterized by 
two one-proton triplets of Н-10 at 7.69–7.48 ppm and Н-9 at 7.99–7.88 ppm and two one-
proton doublets of Н-8 at 7.86–7.68 ppm and Н-11 at 8.56–8.37 ppm. In some cases 
proton H-10 triplet and H-8 doublets of triazinoquinazoline backbone overlapped (3.14, 
3.15,  3.17–3.22) or mentioned protons overlaid the two-proton doublets of phenyl 
substituent (2.2, 3.2), forming multiplet. The p-substituted phenyl fragment in the 3rd 
position of substances 2.2,  2.4,  2.8,  3.1–3.6,  3.8,  3.10,  3.12,  3.16,  3.20  formed A2B2-
system and could be found as two two-proton doublets at 7.39–7.0 ppm and 8.40–8.20 
ppm appropriately. Phenyl radical of substances 2.2, 2.4, 2.8, 3.1–3.6, 3.8, 3.10, 3.12, 
3.16, 3.20 formed sub-spectra consisting of two-proton doublet (Н-2 and Н-6) at 8.35–8.24 
ppm and three-proton  multiplet  (Н-3,  Н-4  and  Н-5) at 7.66–7.53 ppm. Characteristic 
protons of –S-CH2-group of 2.1–2.6, 3.1–3.3, 3.6, 3.11–3.22 were registered as triplet at 
2.83–2.67 ppm, and for substances  3.4–3.10  –  as multiplet at 3.45–2.34 ppm. For 42  G. G. Berest et al.:   
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compounds  2.1-2.6  protons of -СН2-Наl  fixed  as  triplet  at  4.25–3.81 ppm and for 
substances  2.7  and  2.8  –  as multiplet at 3.75–3.74 ppm. Protons of dialkylamino and 
heterylcyclic fragments according to the length or branching had the proper multiplicity in 
the spectra. 
In 
13C NMR spectra Carbon signals in 6th and 2nd positions for compounds 3.2, 3.12, 3.16 
and 3.20 were the most shifted ones and appeared at 159–155 ppm and 160 ppm. Carbon 
of  -SСH2  group was the additional confirmation of structure and the  reaction’s 
S-regioselectivity resonating at 32.31–28.70 ppm.  
Tab. 1.   Bioluminescence intensity, % 
Compd.  Control  Acute action test, mg/mL  Chronic action test, mg/mL 
0.025  0.1  0.25  0.025  0.1  0.25 
DMSO  100.0  100.00  100.00  100.00  100.00  100.00  100.00 
2.1  100.0  111.50  99.10  122.60  150.00  80.00  73.30 
2.2  100.0  98.85  94.25  2.30  100.00  53.33  18.33 
2.3  100.0  81.50  74.50  73.08  122.50  92.50  78.00 
2.4  100.0  52.31  53.85  38.30  72.00  64.00  28.00 
2.5  100.0  100.00  101.02  97.96  16.67  40.67  30.04 
2.6  100.0  75.00  89.29  62.50  150.94  65.94  27.55 
2.7  100.0  102.20  125.20  79.10  66.00  63.60  85.50 
2.8  100.0  125.00  100.00  93.30  64.80  52.00  57.10 
3.1  100.0  67.16  14.93  2.99  0.36  0.00  0.00 
3.2  100.0  64.62  18.46  4.62  0.00  0.00  0.00 
3.3  100.0  23.08  5.77  3.85  0.33  0.00  0.00 
3.4  100.0  81.50  90.00  115.20  93.30  166.40  80.0 
3.5  100.0  124.00  120.00  90.00  90.00  90.00  30.00 
3.6  100.0  35.56  39.56  49.67  77.24  84.32  32.21 
3.7  100.0  125.00  112.50  100.00  84.90  93.60  78.20 
3.8  100.0  93.30  65.50  42.50  39.20  63.30  85.00 
3.9  100.0  100.00  106.0  128.60  104.4  127.7  87.50 
3.10  100.0  100.00  100.9  112.90  57.50  75.60  93.30 
3.11  100.0  105.00  30.00  0.00  60.00  29.33  0.00 
3.12  100.0  97.96  40.82  10.20  0.00  0.00  0.00 
3.13  100.0  49.20  26.50  9.70  0.00  0.00  0.00 
3.14  100.0  33.30  4.00  7.50  0.00  0.00  0.00 
3.15  100.0  91.80  17.70  0.00  100.0  0.00  0.00 
3.16  100.0  10.0  8.00  2.90  0.00  0.00  0.00 
3.17  100.0  60.32  34.92  0.00  1.25  0.00  0.00 
3.18  100.0  83.30  40.00  12.50  30.2  33.3  75.00 
3.19  100.0  100.00  27.91  0.00  58.46  15.38  0.00 
3.20  100.0  64.44  88.89  0.00  0.00  0.00  0.00 
3.21  100.0  100.00  67.91  0.00  48.26  25.64  0.00 
3.22  100.0  89.13  76.09  76.09  56.67  46.26  26.67 
Tetracycline  100.0  80.70  9.10  0.00  0.00  0.00  0.00 
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EI-MS spectra of substances were characterized by the molecular ion absence due to its 
low stability. Formation of F1 ([R1R2N-C2H4]
+•) with the strong intensity in spectrum was the 
main direction of molecule’s fragmentation (compound 3.2 – m/z 112 (12,2%), 3.12 – m/z 
72 (68,2%), 3.16 – m/z 100 (17,2%), 3.21 – m/z 128 (17.6%). Further for F1 rejection of 
one or two atoms of hydrogen and homolytic fragmentation of С–С-bonds with formation of 
stable fragments were characteristic. For 3.2 the EI-MS spectrum with [С2H3N-piperidyl]
+ 
(m/z  111 (100.0)%)), for 3.12  –  with [(Me)2NCH2]
+  (m/z  58 (100.0%)), for 3.16  –  with 
[(Et)2NC2H3]
+ (m/z 99 (100.0%)), for 3.21 – with [(i-Pr)2NC2H3]
+ (m/z 127 (88.8%)), with 
[C3H7NCH]
+  (m/z  70  (96.7%))  and  with  [С3H7]
+  (m/z  43 (100.0%)) were demonstrated. 
Also, additional confirmation of structures was the formation of intensive F2 [C6H5CN]
+ with 
m/z 103 (27.3–10.5%) in the result of the С(2) – С(3) and N(3) – N(4) bonds cleavage of 
triazinoquinazoline system [18–20]. 
Pharmacology and structure-activity relationship 
Bioluminescence inhibition test 
The results of bioluminescence research showed that the majority of compounds appeared 
to be toxic for bacteria Photobacterium leiognathi Sh1 (Table 1). Thus, in chronic action 
test the highest inhibition activity among 6-[ω-halogenalkyl]thio-3-R-2H-[1,2,4]triazino[2,3-
c]quinazoline-2-ones  (2.1–2.8)  showed compounds 2.2,  2.4–2.6,  2.8, that had aryl 
substituent at 3rd position. The elongation of the alkyl fragment from ethyl (2.1, 2.2) to 
isopropyl (2.3–2.6) and butyl (2.7, 2.8) led to decreased cytotoxicity in chronic action test. 
Such SAR also was characteristic for compounds 3.1–3.22. 6-[(2-Dialkylaminoethyl)thio]-
3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones (3.1–3.3, 3.11–3.2) had the highest biocide 
activity in the acute and chronic action tests. Noticeably, substances 3.1–3.3, 3.11–3.22 
possessed biocide activity in concentration of 0.1 and 0.25 mg/mL in the acute and chronic 
actions tests. It is interesting to mention that some of the synthesized compounds (3.1–
3.3, 3.12–3.14, 3.16, 3.17, 3.20) showed effect of hormesis in chronic action test, inhibiting 
the intensity of bioluminescence in concentration of 0.25 mg/mL.  
Thus, the SAR study revealed that:  
1) the most cytotoxic substances against luminescent bacteria Photobacterium leiognathi 
strain Sh1 in acute and chronic test appeared to be compounds 3.1–3.22;  
2) substances 3.1–3.22 demonstrated inhibitive activity with the increase of concentration 
to 0.1 and 0.25 mg/mL;  
3) cytotoxicity of 6-{[ω-(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-
ones (3.1–3.10) is determined by the length of alkyl moiety and decreases in range 
Et<Pr<Bu;  
4) replacement of heteryl fragment of compounds 3.1–3.3 by dialkylamino group (3.11–
3.22) does not lead to change of cytotoxic activity in chronic test. 
Thus, compounds with the highest cytotoxic activity appeared to be 6-[(2-dialkyl-
aminoethyl)thio]-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones (3.1–3.3, 3.11–3.22), that 
could be the indicator of potential presence of antifungal, antibacterial or anticancer activity 
of the mentioned compounds. 44  G. G. Berest et al.:   
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Tab. 2.   Antimicrobial activity of synthesized compounds 
Compd.
a  mg/mL  The inhibitory zones of the investigated compounds, mm 
E. coli  S. aureus  M. luteum  C. tenuis  A. niger 
3.1  5.0  0  0  25  0  0 
3.1  1.0  0  0  10  0  0 
3.2  5.0  0  0  23  0  0 
3.2  1.0  0  0  18  0  0 
3.3  5.0  0  0  20  0  0 
3.3  1.0  0  0  16  0  0 
3.4  5.0  0  0  12  0  0 
3.5  5.0  0  0  10  0  0 
3.6  5.0  0  0  8  0  0 
3.7  5.0  0  0  16  0  0 
3.8  5.0  0  0  15  0  0 
3.9  5.0  0  0  12  0  0 
3.10  5.0  0  0  13  0  0 
3.11  5.0  0  0  8  0  0 
3.12  5.0  0  12  26  0  0 
3.12  1.0  0  0  14  0  0 
3.13  5.0  0  9  23  0  6
b 
3.13  1.0  0  0  16  0  0 
3.14  5.0  0  0  9  0  0 
3.15  5.0  0  0  12  0  0 
3.16  5.0  0  8  24  0  0 
3.16  1.0  0  0  12  0  0 
3.17  5.0  0  12  20  0  12
b 
3.17  1.0  0  0  7  0  0 
3.18  5.0  0  13  21  8  23
b 
3.18  1.0  0  7  15  0  0 
3.19  5.0  0  0  7  0  0 
3.20  5.0  0  0  28  0  0 
3.20  1.0  0  0  17  0  0 
3.21  5.0  0  0  12  0  0 
3.21  1.0  0  0  8  0  0 
3.22  5.0  0  0  7  0  0 
Vancomicin  0.1  16  18  58  0  0 
Nystatin  0.1  0  11  15  24  25 
Oxacillin  0.1  0  21  0  0  0 
a compounds 2.1–2.8 at concentration of 1.0 and 5.0 mg/mL didn’t inhibit investigated bacteria;  
b zone of late spore formation of Aspergillus niger (without inhibition of fungus mycelium). 
 
Antimicrobial and antifungal activities 
The results of antimicrobial screening showed that researched substances had significant 
antimicrobial activity only against cereous bacteria Mycobacterium luteum (Table 2). Thus, 
the highest antibacterial data were established for 6-[(2-dialkylaminoethyl)thio]-3-R-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-ones  (3.1–3.3,  3.11–3.22), that inhibited growth of   Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline… 45 
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Gram-positive bacteria M. luteum at 7-28 mm. Increasing the concentration of compounds 
3.1–3.3, 3.11–3.22 from 1.0 to 5.0 mg/mL also led to considerable growth of bactericidal 
activity, while elongation of alkyl substituent (3.4–3.10) resulted in decreased activity and 
frequently appeared only in concentration of 5.0 mg/mL. It is significant that researched 
compounds did not show bactericidal action against E. coli, St.aureus and Candida tenuis. 
The only compounds that had antibacterial activity against St. aureus, inhibiting its growth 
at 7-13 mm were 3.12, 3.13, 3.17 and 3.18. It is also interesting that compounds 3.13, 3.17 
and 3.18 caused the late spore formation of A. niger at 18-23 mm in concentration 0.5 
mg/mL.  
The SAR study revealed that:  
1) antimicrobial activity of researched compounds is more expressed for 6-{[ω-(dialkyl-
amino(heterocyclyl)alkyl]thio}-  (3.1–3.22) than for corresponding (ω-halogenoalkyl)thio-
derivatives of 3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones (2.1–2.8);  
2) the main factor for antimicrobial activity demonstration for substances 2.1–2.8, 3.1–3.22 
against S. aureus is introduction of the [2-(dialkylamino)ethyl]thio]- substituent in the 6th 
position, but elongation of radical up to propyl or butyl leads to its significant reduction;  
3) antimicrobial activity against M. luteum is characteristic for the majority of compounds, 
and compounds with phenyl, thionyl or р-methoxyphenyl substituents at 3rd position have 
the strongest activity.  
So,  6-[(2-dialkylaminoethyl)thio]-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones  (3.1–3.3, 
3.11–3.22) had the highest antimicrobial activity against M. luteum, testifying the potential 
presence of antituberculosis activity of the mentioned compounds.  
Anticancer assay for preliminary in vitro testing 
Newly synthesized compounds were selected by the National Cancer Institute (NCI) 
Developmental Therapeutic Program for the in vitro cell line screening to investigate their 
anticancer activity. Compounds 3.1, 3.14–3.16, 3.18, 3.21 were submitted and evaluated 
according to the US NCI protocol [23–28]. The compounds were first evaluated at one 
dose primary anticancer assay toward or approximately 60 cell lines (concentration 10
−5 
M). The human tumor cell lines were derived from nine different cancer types: leukemia, 
melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancers. In the screening 
protocol, each cell line was inoculated and preincubated for 24–48 h on a microtiter plate. 
Test agents were then added at a single concentration and the culture was incubated for 
an additional  48 h. End point determinations were made with a protein binding dye, 
sulforhodamine B (SRB). Results for each test agent were reported as the percent growth 
of the treated cells when compared to the untreated control cells. The preliminary 
screening results are shown in Table 3. 
Investigation of the compounds 3.1, 3.14–3.16, 3.18, 3.21 showed that individual cell lines 
had different sensitivity towards synthesized compounds in concentration 10
−5 М (Table 3). 
Thus, substance  3.1  exhibited cytotoxicity against cell lines of leukemia (CCRF-CEM, 
HL-60(TB)). Change the phenyl substituent in position 3 (3.1) by methyl led to the 
substantial reduction of activity against cell lines of leukemia. Synthesized compounds that 
had at the 3rd position р-methoxyphenyl and р-methylphenyl (3.21) group possessed 46  G. G. Berest et al.:   
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strong cytotoxicity against the majority of the cancer cell lines. It is interesting that the 
significant antiproliferative activity was characteristic for compound 3.18 against leukemia 
cell lines (K-562, MOLT-4, RPMI-8226, SR), non-small cell lung cancer (A549/ATCC, 
HOP-62, HOP-92, NCI-H322M, NCI-H460), colon cancer (COLO 205, HCT-116, HCT-15, 
HT29, KM12, SW-620), CNS cancer (SF-539, U251), melanoma (LOX IMVI, MALME-3M), 
ovarian cancer (IGROV1, OVCAR-3, OVCAR-4, OVCAR-8, NCI/ADR-RES), renal cancer 
(ACHN, RXF 393, SN12C, UO-31), prostate cancer (PC-3, DU-145) and breast cancer 
(MCF7, MDA-MB-231/ATCC). Furthermore, compounds 3.1, 3.14, 3.18 showed antitumor 
activity, notably 3.1 against leukemia cell lines (CCRF-CEM, HL-60(TB)), 3.14 – against 
leukemia SR, 3.18 – against leukemia SR and non-small cell lung cancer (A549/ATCC, 
NCI-H460). 
Tab. 3.   Cytotoxic activity of the compounds in conc. 10
−5 M against 60 cell cancer lines 
Cpd.  Mean  
growth, % 
Range of  
growth, %  Most sensitive cell line growth, %
a 
3.1  98.17  −39.37–137.18  −39.37 (ССRF-CEM/L), −8.71 (HL-60(TB)/L), 56.76 
(SR/L) 
3.14  64.02  −9.70–111.63 
45.39 (ССRF-CEM/L), 38.21 (HL-60(TB)/L), 2.60 (K-
562/L), 3.07 (MOLT-4/L), 61.63 (RPMI-8226/L), −9.70 
(SR/L), 32.00 (A549/ATCC/nscLC), 24.43 (NCI-
H460/nscLC), 41.37 (NCI-H522/nscLC), 32.77 (HCT-
116/ColC), 27.77 (HT29/ColC), 38.36 (KM12/ColC), 
32.21 (SW-620/ColC), 58.33 (SF-268/CNSC), 54.01 
(SF-539/CNSC), 43.12 (LOX IMVI/M), 56.09 (OVCAR-
3/OV), 38.05 (OVCAR-8/OV), 32.25 (ACHN/RC) 
3.15  102.73  47.89–120.73  51.70 (K-562/L), 47.89 (MOLT-4/L) 
3.16  36.73  3.14–86.74 
27.70 (ССRF-CEM/L), 14.32 (K-562/L), 14.03 (MOLT-
4/L), 22.57 (RPMI-8226/L), 3.14 (SR/L), 16.17 
(A549/ATCC/nscLC), 50.95 (EKVX/nscLC), 39.76 
(HOP-62/nscLC), 50.31 (NCI-H226/nscLC), 56.43 
(NCI-H23/nscLC), 14.76 (NCI-H460/nscLC), 5.40 
(NCI-H522/nscLC), 20.35 (COLO 205/ColC), 51.28 
(HCC-2998/ColC), 27.21 (HCT-116/ColC), 30.10 
(HCT-15/ColC), 5.98 (HT29/ColC), 32.28 
(KM12/ColC), 27.71 (SW-620/ColC), 49.83 (SF-
268/CNSC), 36.94 (SF-295/CNSC), 36.17 (SF-
539/CNSC), 44.31 (SNB-75/CNSC), 27.70 
(U251/CNSC), 25.46 (LOX IMVI/M), 36.43 (MDA-MB-
435/M), 23.34 (SK-MEL-2/M), 37.44 (SK-MEL-5/M), 
3.33 (UACC-257/M), 46.99 (UACC-62/M), 45.11 
(OVCAR-3/OV), 49.28 (OVCAR-4/OV), 23.91 
(OVCAR-8/OV), 41.06 (NCI/ADR-RES/OV), 49.73 
(SK-OV-3/OV), 39.89 (786-0/RC), 45.41 (A498/RC), 
24.31 (ACHN/RC), 41.64 (RXF 393/RC), 41.33 
(SN12C/RC), 24.20 (TK-10/RC), 47.06 (PC-3/PC), 
26.87 (DU-145/PC), 14.90 (MCF7/BC), 37.92 (T-
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Tab. 3.   (Cont.) 
Cpd.  Mean  
growth, % 
Range of  
growth, %  Most sensitive cell line growth, %
a 
3.18  46.48  −86.89–108.61 
5.24 (K-562/L), 20.57 (MOLT-4/L), 37.58 (RPMI-
8226/L), −17.24 (SR/L), −38.73 (A549/ATCC/nscLC), 
48.66 (HOP-62/nscLC), 40.55 (HOP-92/nscLC), 36.24 
(NCI-H322M/nscLC), −86.89 (NCI-H460/nscLC), 
36.93 (COLO 205/ColC), 39.88 (HCT-116/ColC), 
33.86 (HCT-15/ColC), 3.67 (HT29/ColC), 32.42 
(KM12/ColC), 12.48 (SW-620/ColC), 24.34 (SF-
539/CNSC), 24.54 (U251/CNSC), 10.18 (LOX 
IMVI/M), 40.06 (MALME-3M/M), 25.90 (IGROV1/OV), 
47.44 (OVCAR-3/OV), 42.39 (OVCAR-4/OV), 31.58 
(OVCAR-8/OV), 56.28 (NCI/ADR-RES/OV), 32.69 
(ACHN/RC), 55.08 (RXF 393/RC), 46.16 (SN12C/RC), 
10.63 (UO-31/RC), 55.51 (PC-3/PC), 35.97 (DU-
145/PC), 27.57 (MCF7/BC), 56.58 (MDA-MB-
231/ATCC/BC) 
3.21  85.86  −36.39–128.76 
52.74 (HL-60(TB)/L), −36.39 (K-562/L), −25.77 (SR/L), 
53.52 (NCI-H460/nscLC), 22.86 (HCT-116/ColC), 7.75 
(SW-620/ColC), 10.81 (MDA-MB-435/M) 
L…leukemia; nscLC…non-small cell lung cancer; ColC…colon cancer; CNSC…CNS cancer; M…melanoma; 
OV…ovarian cancer; RC…renal cancer; PC…prostate cancer; BC…breast cancer. 
 
The dose-dependent action in 5 concentrations according to standard procedure of NCI 
(100μM–0.01μM) was researched for 3.14, 3.16, 3.18. The 3 dose-dependent parameters 
were calculated: 1) GI50 – molar concentration of the compound that inhibits 50% net cell 
growth; 2) TGI – molar concentration of the compound leading to total inhibition of cell 
growth; 3) LC50 – molar concentration of the compound leading to 50% net cell death. If 
logarithmic data of researched parameters (log GI50, log TGI та log LC50) was less than 
−4.00, substances were marked as active. For  each of the  parameters the average 
experimental data were calculated (mean graph midpoints, MG_MID) (Table 4). 
Tab. 4.   Summary of anticancer screening data at dose-dependent assay 
Comp.  N
a  log GI50  log TGI  log LC50 
N1
b  Range  MG_MID  N2
b  Range  MG_MID  N3
b  Range  MG_MID 
3.14  57  −55  −6.07 to 
−5.01  −5.48  17  −5.53 to 
−4.02  −4.21  5  −5.46 to 
−4.04  −4.05 
3.16  59  59  −6.29 to 
−5.31  −5.52  58  −5.44 to 
−4.64  −4.89  50  −5.11 to 
−4.07  −4.32 
3.18  59  59  −6.29 to 
−5.31  −5.57  59  −5.54 to 
−4.55  −5.04  56  −5.24 to 
−4.01  −4.51 
a N – number of human tumor cell lines tested at the 2nd stage assay; 
b N1, N2, N3 – number of sensitive cell lines, against which the compound possessed considerable growth 
inhibition according to mentioned parameter (log GI50, log TGI and log LC50 ≤ 4.00). 
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The parameters of compounds activity against the most sensitive cell lines are shown in 
the table 5 (log GI50 ≤−5.65). It is necessary to mention the selective sensitivity to cell lines 
of CNS cancer (SF-539, SNB-75), renal cancer (ACHN), melanoma (LOX IMVI) and renal 
cancer (ACHN) of compounds 3.14,  3.16  and  3.18. Thus, 3.14  revealed high level of 
inhibition (log GI50 = −6.07) against cell line SNB-75 of СNS cancer (MG_MID log GI50 = 
−5.48 for 55 cell lines), 3.16 (log GI50 = −6.29) – against cell line A498 of renal cancer 
(MG_MID log GI50 = −5.52 for 59 cell lines), 3.18 (log GI50 = −6.20) – against cell line 
HOP-92 of NSC lung cancer (MG_MID log GI50 = −5.57 for 59 cell lines). 
Tab. 5.   The influence of compounds 3.14, 3.16 and 3.18 on the growth of individual 
tumor cell lines (log GI50 ≤−5.65) 
Cpd.  Cancer  Cell line  log GI50  log TGI  Log LC50 
3.14 
Leukemia  RPMI-8226  −5.70  > −4.00  > −4.00 
SR  −5.83  > −4.00  > −4.00 
NSC lung cancer  A549/ATCC  −5.66  > −4.00  > −4.00 
Colon cancer  HCT-116  −5.66  −4.97  > −4.00 
HT29  −5.74  > −4.00  > −4.00 
CNS cancer  SF-539  −5.80  −5.50  −5.21 
SNB-75  −6.07  −4.90  −4.36 
Melanoma  LOX IMVI  −5.88  −5.53  −5.18 
Renal cancer 
A498  −5.88  −4.51  > −4.00 
ACHN  −5.88  −5.46  −5.46 
CAKI-1  −5.94  > −4.00  > −4.00 
UO-31  −5.79  −4.61  > −4.00 
3.16 
Colon cancer  COLO 205  −5.76  −5.37  −4.93 
HT29  −5.66  −4.91  > −4.00 
CNS cancer  SF-539  −5.67  −5.22  −4.62 
SNB-75  −5.72  −4.87  −4.43 
Melanoma 
LOX IMVI  −5.76  −5.44  −5.11 
SK-MEL-5  −5.66  −5.23  −4.67 
UACC-257  −5.68  −5.29  −4.77 
Renal cancer 
A498  −6.29  −5.21  −4.51 
ACHN  −5.68  −4.93  −4.33 
CAKI-1  −5.66  −4.98  −4.07 
UO-31  −5.79  −5.07  −4.43 
3.18 
Leukemia  RPMI-8226  −5.71  −5.31  −4.51 
NSC lung cancer 
A549/ATCC  −5.77  −5.48  −5.20 
HOP-92  −6.20  −5.14  −4.47 
NCI-H460  −5.80  −5.49  −5.19 
NCI-H522  −5.80  −5.49  −5.18 
Colon cancer 
COLO 205  −5.88  −5.54  −5.20 
HCT-116  −5.93  −5.42  −4.79 
HT29  −5.96  −5.50  −5.03 
SW-620  −5.65  −4.96  −4.43 
CNS cancer 
SF-539  −5.79  −5.45  −5.10 
SNB-75  −5.81  −5.33  −4.70 
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Tab. 5.   (Cont.) 
Cpd.  Cancer  Cell line  log GI50  log TGI  Log LC50 
3.18 
Melanoma  LOX IMVI  −5.89  −5.28  −4.61 
  MALME-3M  −5.68  −5.29  −4.65 
  SK-MEL-5  −5.74  −5.34  −4.86 
  UACC-257  −5.79  −5.51  −5.24 
  UACC-62  −5.79  −5.38  −4.79 
Ovarian cancer  OVCAR-3  −5.78  −5.46  −5.15 
  OVCAR-4  −5.75  −5.33  −4.82 
  OVCAR-8  −5.84  −5.46  −5.08 
Renal cancer  786-0  −5.73  −5.33  −4.84 
  ACHN  −5.81  −5.20  −4.45 
  RXF 393  −5.75  −5.34  −4.74 
Prostate cancer  PC-3  −5.70  −5.01  −4.47 
Breast cancer  MCF7  −5.81  −5.39  −4.90 
  MDA-MB-231/ATCC  −5.76  −5.17  −4.48 
  MDA-MB-468  −5.75  −5.37  −4.98 
 
It is important to note that compound 3.14 had the highest anticancer activity against cell 
lines of leukemia (LogGI50 = −5.66), CNS cancer (LogGI50 = −5.60), renal cancer (LogGI50 
= −5.60); 3.16 – against cell lines of renal cancer (LogGI50 = −5.67); 3.18 – against cell 
lines of colon cancer (LogGI50  =  −5.69), CNS cancer (LogGI50  =  −5,59), melanoma 
(LogGI50 = −5.62), renal cancer (LogGI50 = −5.58) (Figure 1). 
 
Fig. 1.   Anticancer selectivity pattern of the most active compounds 3.14, 3.16 and 
3.18. 
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SAR study revealed that 3-R-6-thio-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones derivatives 
are the class of insufficiently studied annelated quinazolines with triazines substances with 
promising anticancer activity. It is important that antitumor activity of compounds 3.1, 3.14–
3.16, 3.18, 3.21 is determined by:  
1) the heterocycle skeleton;  
2) substituent at the 3rd position with increasing activity in the range of 
Me<Ph<4-MePh<4-MeOPh;  
3) substituents at the 6th position, namely dialkylamino(heterocyclil)alkyl fragment 
connected by Sulphur with heterocyclic system, gaining the activity in range of 
Me<i-Pr<Pyr<Et. Thus, it is interesting to modify  the «lead-compounds» among the 
[1,2,4]triazino[2,3-c]quinazoline derivatives for further pharmacological investigations.  
COMPARE analysis and molecular mechanism assumptions 
We have also performed COMPARE analyses for all the active compounds to investigate 
the similarity of their cytotoxicity (mean graph fingerprints) with those of known anticancer 
standard agents, NCI active synthetic compounds and natural extracts, which are present 
in public available databases [29–32]. Such analysis is based on comparing the patterns of 
differential growth inhibition for cultured cell lines and can potentially gain insight into the 
mechanism of the cytotoxic action. It determines Pearson correlation coefficient (PCC) for 
the degree of similarity of mean graph fingerprints obtained from in vitro anticancer screen 
with patterns of activity of standard agents. We performed COMPARE computations for 
synthesized compounds against the NCI ‘Standard Agents’ database at the GI50  level 
(correlations PCC >0.4) (Table 6). 
COMPARE analysis hypothesis precludes that the compounds 3.14, 3.16 and 3.18 might 
have the same mechanism of action as the agent with known action mechanism, if the 
data pattern of a compound correlates well with the data pattern of compounds belonging 
to the standard agent database. The majority of significant correlations for 3-R-6-thio-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-ones  derivatives were found with inhibitor of 
topoisomerases I and II, as well as inhibition or promotion of microtubules polymerization 
and CTP-synthase inhibitor. These molecular targets should be considered as the first 
priority and be explored for the leukemia, colon, CNS, renal cancers cell lines.  
Experimental 
Chemistry 
General methods 
Melting points were determined in open capillary tubes and were uncorrected. The 
elemental analyses (C, H, N, S) were performed using the ELEMENTAR vario EL Cube 
analyzer (USA). Analyses were indicated by the symbols of the elements or functions 
within ±0.3% of the theoretical values. IR spectra (4000–600 cm
–1) were recorded on a 
Bruker ALPHA FT-IR spectrometer (Bruker Bioscience, Germany) using a module for 
measuring attenuated total reflection (ATR). 
1H NMR spectra (500 MHz) and 
13C NMR 
spectra (100 MHz): were recorded on a Varian-Mercury 400 (Varian Inc., Palo Alto, CA, 
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recorded using chromatography / mass spectrometric system which consists of high 
performance liquid chromatograph «Agilent 1100 Series» (Agilent, Palo Alto, CA, USA) 
equipped with diode-matrix and mass-selective detector «Agilent LC/MSD SL» 
(atmospheric pressure chemical ionization – APCI). Electron impact mass spectra (EI-MS) 
were recorded on a Varian 1200 L instrument at 70 eV (Varian, USA). The purity of all 
obtained compounds was checked by 
1H-NMR and LC-MS.  
Tab. 6.   COMPARE analysis of tested compounds
a 
Cpd. 
No.  PCC  Target 
Target  
vector  
NSC 
Cell  
lines 
Seed  
StDev 
Target  
StDev 
Target mechanism of 
action
b 
3.14 
0.601  Maytansine  S153858  57  0.299  0.697 
inhibit or promote 
polymerization of 
microtubules 
0.556  Vinblastine 
sulfate  S49842  56  0.300  0.587 
inhibit or promote 
polymerization of 
microtubules 
0.523  Aclacino-
mycin A  S208734  48  0.238  0.135 
inhibiting or preventing 
the proliferation of 
neoplasms 
0.485  Batracylin  S320846  42  0.239  0.271 
inhibitor of DNA 
topoisomerases I and II 
induces histone 
gamma-H2AX 
0.477  Vincristine 
sulfate  S67574  57  0.299  0.647 
inhibit or promote 
polymerization of 
microtubules 
0.474  Morpholino-
ADR  S354646  57  0.299  0.368 
inhibits the progression 
of the enzyme 
topoisomerase II 
0.438  N,N-dibenzyl-
daunomycin  S268242  48  0.238  0.449  inhibitor topoisomerase 
II 
3.16 
0.514  Batracylin  S320846  43  0.130  0.274 
inhibitor of DNA 
topoisomerases I and II 
induces histone 
gamma-H2AX 
0.444  Cyclopentenyl
cytosine  S5375575  51  0.122  0.903 
CTP synthetase 
inhibitor (conversion 
UTP to CTP) 
3.18  0.460  Hycanthone  S142982  53  0.272  0.220 
inducer of nuclear 
immunoreactivity to 
antinucleoside 
antibodies in HeLa cells 
a Only correlations with PCC≥ 0.4 were selected, as significant;  
b Putative mechanisms of action were identified with the use of literature sources. 
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Substances  1.1–1.4  were synthesized according to the reported procedures [18, 21]. 
Other starting materials and solvents were obtained from commercially available sources 
and used without additional purification. 
General procedure for synthesis of 6-[(ω-halogenoalkyl)thio)-3-R-2H-[1,2,4]triazino-
[2,3-c]quinazolin-2-ones (2.1–2.8).  
To a 0.01 M solution of 3-R-6-thio-6,7dihydro-2H-[1,2,4]triazino[2,3-c]quinazoline-2-one 
potassium salt (1.1–1.4) in 20 ml of propan-2-ol–water mixture (5:1) was added a solution 
of 0.01 M of 1,2-dibromoethane, 1-bromo-3-chloropropane or 1-bromo-4-chlorobutane in 
10 ml of propan-2-ol. Reaction mixture was heated for 10–20 min, cooled, precipitate was 
filtered and dried. Formed precipitates were recrystallized from ethanole and propan-2-ol. 
6-[(2-Bromoethyl)thio]-3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.1).  Yield: 
55.7%,  M.p. 196–200°C;  IR (cm
−1): 3106, 2917, 2850, 2533, 1727, 1659, 1618, 1605, 
1582, 1517, 1482, 1376, 1341, 1297, 1258, 1196, 1156, 1107, 1058, 982, 960, 881, 811, 
773, 750, 726, 682, 666, 615; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.36 (s, 3Н, CH3), 
3.38 (t, 2Н, -S-CН2-), 4.20 (t, 2Н, -S-CН2-CH2-), 7.48 (t, 1H, J
3 = 7.7, H-10), 7.68 (d, 1H, J 
= 7.9, H-8), 7.88 (t, 1H, J
3 = 7.7, J
4 = 1.4, H-9), 8.43 (d, 1H, J = 7.9, H-11); Anal. calcd. for 
C13H11BrN4OS: C, 44.46; Н, 3.16; Br, 22.75; N, 15.95; S, 8.13; Found: C, 44.44; Н, 3.13; 
Br, 22.74; N, 15.96; S, 8.14. 
6-[(2-Bromoethyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.2).  Yield: 
72.9%, M.p. 192–195°C;  IR (cm
−1):  3096, 2948, 2922, 2861, 1644, 1623, 1606, 1572, 
1538, 1494, 1475, 1439, 1373, 1347, 1298, 1281, 1256, 1234, 1178, 1134, 1114, 1080, 
1047, 1030, 1002, 986, 942, 883, 872, 858, 814, 768, 756, 695, 656, 607; 
1H-NMR (500 
MHz, DMSO-d6, TMS): δ=3.52 (t, 2Н, -S-CН2-), 4.25 (t, 2Н, -S-CН2-CH2-), 7.53-7.48 (m, 
4Н, Н-3´, 5´ 3-Ph, Н-8, 10), 7.76-7.67 (m, 2Н, Н-4´ 3-Ph, Н-9), 8.31 (d, 2Н, J=7.8, Н-
2´,6´3-Ph), 8.37 (d, 1Н, J=7.9, Н-11); Anal. calcd. for C18H13BrN4OS: C, 52.31; Н, 3.17; Br, 
19.33; N, 13.56; S, 7.76; Found: C, 52.32; Н, 3.19; Br, 19.34; N, 13.58; S, 7.78. 
6-[(3-Chloropropyl)thio]-3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.3).  Yield: 
87.5%,  M.p. 199–201°C;  IR (cm
−1): 1660, 1625, 1603, 1580, 1556, 1499, 1466, 1429, 
1362, 1342, 1311, 1285, 1261, 1222, 1210, 1132, 1104, 1060, 1043, 996, 954, 884, 863, 
772, 700, 686, 655, 631, 607; 
1H-NMR  (500 MHz, DMSO-d6,  TMS):  δ=2.25 (qui, 2H, 
J=6.4, -S-CH2-CH2-), 2.38 (s, 3Н, CН3), 3.38 (t, 2H, J=6.4, -S-CH2-), 3.82 (t, 2H, J=6.4, -S-
CH2-CH2-CH2-), 7.66 (t, 1Н, J=7.7, Н-10), 7.76 (d, 1Н, J=7.9, Н-8), 7.96 (t, 1Н, J=7.7, Н-9), 
8.46  (d,  1Н,  J=7.9,  Н-11); LC-MS,  m/z  =  321 [M+1], 324 [M+4]; Anal. calcd. for 
C19H15ClN4OS: C, 52.42; Н, 4.08; Cl, 11.05; N, 17.46; S, 9.99; Found: C, 52.42; Н, 4.09; 
Cl, 11.04; N, 17.43; S, 9.98. 
6-[(3-Chloropropyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.4).  Yield: 
84.9%, M.p. 168–170°C;  IR (cm
−1): 3055, 2924, 1659, 1586, 1566, 1550, 1502, 1486, 
1466, 1442, 1398, 1372, 1339, 1310, 1284, 1264, 1234, 1215, 1183, 1157, 1135, 1100, 
1078, 1030, 1002, 988, 959, 939, 873, 852, 811, 764, 747, 706, 685, 667, 651, 631; 
1H-
NMR  (500 MHz, DMSO-d6, TMS):  δ=2.27 (qui, 2H, J=6.4,  -S-CH2-CH2-), 3.40 (t, 2H, 
J=6.4, -S-CH2-), 3.84 (t, 2H, J=6.4, -S-CH2-CH2-CH2-), 7.63-7.56 (m, 3Н, Н-3´,4´, 5´ 3-Ph), 
7.68 (t, 1Н, J=7.7, Н-10), 7.79 (d, 1Н, J=7.9, Н-8), 7.97 (t, 1Н, J=7.7, Н-9), 8.28 (d, 2Н, 
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[M+4];  Anal. calcd. for C19H15ClN4OS:  C,  59.60;  Н,  3.95;  Cl,  9.26;  N,  14.63;  S,  8.37; 
Found: C, 59.60; Н, 3.95; Cl, 9.24; N, 14.63; S, 8.37. 
6-[(3-Chloropropyl)thio]-3-(4-methylphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.5). 
Yield: 84.7%, M.p. 179–182°C;  IR (cm
−1): 3245, 2923, 1761, 1661, 1626, 1610, 1587, 
1562, 1549, 1497, 1469, 1403, 1367, 1339, 1307, 1266, 1241, 1185, 1156, 1139, 1108, 
1074, 1021, 989, 964, 940, 880, 856, 833, 771, 713, 686, 641, 627; 
1H-NMR (500 MHz, 
DMSO-d6, TMS): δ=2.28 (qui, 2H, J=6.4, -S-CH2-CH2-), 2.42 (s, 3Н, CН3), 3.42 (t, 2H, 
J=6.4, -S-CH2-), 3.84 (t, 2H, J=6.4, -S-CH2-CH2-CH2-), 7.39 (d, 2Н, J=7.9, Н-3´,5´ Ph)), 
7.68 (t, 1Н, J=7.7, Н-10), 7.79 (d, 1Н, J=7.9, Н-8), 7.97 (t, 1Н, J=7.7, Н-9), 8.23 (d, 2Н, 
J=7.9, Н-2´,6´ Ph), 8.49 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 397 [M+1], 399 [M+3], 400 
[M+4];  Anal. calcd. for C20H17ClN4OS:  C,  60.52;  Н,  4.32;  Cl,  8.93;  N,  14.12;  S,  8.08; 
Found: C, 60.51; Н, 4.30; Cl, 8.94; N, 14.12; S, 8.06. 
6-[(3-Chloropropyl)thio]-3-(4-methoxyphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one 
(2.6).  Yield: 84.8%, M.p. 177–183°C;  IR (cm
−1): 3234, 2973, 2924, 2894, 2838, 1761, 
1657, 1630, 1603, 1585, 1562, 1541, 1489, 1470, 1453, 1409, 1385, 1341, 1321, 1303, 
1255, 1240, 1173, 1140, 1088, 1046, 988, 941, 908, 879, 853, 837, 809, 758, 715, 705, 
682, 636, 623; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.31 (qui, 2H, J=6.4, -S-CH2-CH2-
), 3.44 (t, 2H, J=6.4, -S-CH2-), 3.81 (t, 2H, J=6.4, -S-(CH2)2-CH2-), 3.90 (s, 3Н, CН3О), 
7.06 (d, 2Н, J=8.9, Н-3´,5´ Ph), 7.66 (t, 1Н, J=7.7, Н-10), 7.78 (d, 1Н, J=7.9, Н-8), 7.94 (t, 
1Н, J=7.7, Н-9), 8.40 (d, 2Н, J=8.9, Н-2´,6´ Ph), 8.53 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 
413 [M+1], 415 [M+3], 417 [M+4]; Anal. calcd. for C20H17ClN4O2S: C, 58.18; Н, 4.15; Cl, 
8.59; N, 13.57; S, 7.77; Found: C, 58.18; Н, 4.15; Cl, 8.58; N, 13.57; S, 7.77. 
6-[(3-Chlorobutyl)thio]-3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.7).  Yield: 
87.5%,  M.p. 199-201°C;  IR (cm
−1):  2962, 2910, 1660, 1581, 1557, 1501, 1464, 1425, 
1360, 1337, 1309, 1280, 1254, 1219, 1203, 1130, 1101, 1034, 1001, 950, 882, 858, 787, 
767, 700, 688, 629, 605; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=1.96 (m, 4H, -S-CH2-
(CH2)2-), 2.39 (s, 3Н, CН3), 3.33 (m, 2H, -S-CH2-), 3.74 (m, 2H, -S-(CH2)3-CH2-), 7.66 (t, 
1Н, J=7.7, Н-10), 7.77 (d, 1Н, J=7.9, Н-8), 7.96 (t, 1Н, J=7.7, Н-9), 8.49 (d, 1Н, J=7.9, Н-
11); LC-MS, m/z = 335 [M+1], 337 [M+3], 338 [M+4]; Anal. calcd. for C15H15ClN4OS: C, 
63.81; Н, 4.52; Cl, 10.59; N, 16.73; S, 9.58; Found: C, 63.81; Н, 4.52; Cl, 10.58; N, 16.73; 
S, 9.58. 
6-[(3-Chlorobutyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (2.8).  Yield: 
87.5%,  M.p. 199-201°C;  IR (cm
−1):  3072, 2937, 2857, 1666, 1585, 1553, 1503, 1487, 
1470, 1444, 1404, 1370, 1341, 1312, 1285, 1262, 1243, 1217, 1182, 1137, 1105, 1080, 
1022, 1002, 989, 940, 879, 850, 812, 782, 767, 754, 689, 653, 614; 
1H-NMR (500 MHz, 
DMSO-d6, TMS): δ=2.06 (m, 4H, -S-CH2-(CH2)2-), 3.46 (m, 2H, -S-CH2-), 3.75 (m, 2H, -S-
(CH2)3-CH2-), 7.63-7.56 (m, 3Н, Н-3´,4´, 5´ Ph), 7.69 (t, 1Н, J=7.7, Н-10), 7.80 (d, 1Н, 
J=7.9, Н-8), 7.99 (t, 1Н, J=7.7, Н-9), 8.29 (d, 2Н, J=7.3, Н-2´,6´ Ph), 8.51 (d, 1Н, J=7.9, Н-
11); LC-MS, m/z = 397 [M+1], 399 [M+3], 400 [M+4]; Anal. calcd. for C20H17ClN4OS: C, 
60.52; Н, 4.32; Cl, 8.93; N, 14.12; S, 8.08; Found: C, 60.52; Н, 4.33; Cl, 8.94; N, 14.13; S, 
8.10. 
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General procedure for synthesis of 6-[(ω-dialkylamino(heterocyclyl-)alkyl)thio]-
3-R-2H-[1,2,4]triazino[2,3-c]quinazolin-2-ones (3.1–3.22).  
Method A.  To a stirred suspension of 0.01 M of 6-[ω-halogenalkyl]thio-3-R-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-one (2.1–2.4, 2.7, 2.8) in 20 ml of propan-2-ol or dioxane 
was added 0.03-0.04 M of proper amine (pyrrolidine, piperidine, morpholine) and 0.01 M of 
potassium iodide. The resulting mixture was refluxed for 10 h. After cooling the resulting 
mixture was poured in water, substances 3.1–3.10  were extracted by diethyl ether or 
chloroform. Organic solvent was removed. Formed precipitates were recrystallized from 
ethanol. 
Method B.  To a stirred suspension of 0.01 M of potassium salt of 3-R-6-thio-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-one  (2.1–2.6)  in 20 ml mixture of propan-2-ol–water 
(5:1) or propan-2-ol  was added 0.17 ml (0.001M) of triethylamine and 0.01 M of (2-
chloroethyl)-N,N-dialkylamine  hydrochloride  or  of 1-(2-chloroethyl)heterocycle  hydro-
chloride. The resulting mixture was refluxed for 30–90 min. Solution was cooled, poured in 
water,  obtained compounds 3.1–3.3,  3.11–3.22  were extracted by diethyl ether or 
chloroform. Organic solvent was removed. Formed precipitates were recrystallized from 
ethanol and dried. 
3-Phenyl-6-[(2-pyrrolidin-1-ylethyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.1). 
Yield: Method A, 30.6%; Method B, 70.6%; M.p. 172–174°C; IR (cm
−1): 2955, 2930, 2874, 
2798, 1730, 1662, 1587, 1564, 1550, 1504, 1485, 1469, 1455, 1372, 1341, 1309, 1285, 
1266, 1244, 1232, 1180, 1138, 1110, 1078, 1031, 1002, 987, 939, 903, 880, 852, 810, 
788, 778, 750, 686, 654, 623; 
1H-NMR  (500 MHz, DMSO-d6, TMS):  δ=1.70 (qui,  4Н, 
N(CH2)2(CH2)2), 2.49 (qui, 4Н,  N(CH2)2), 2.67 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.41 (t, 2Н, 
J=6.9, -S-CH2-), 7.65-7.57 (m, 3Н, Н-3´,4´,5´ Ph), 7.64 (t, 1Н, J=7.3, Н-10), 7.73 (d, 1Н, 
J=7.9, Н-8), 7.96 (t, 1Н, J=7.3, Н-9), 8.24 (d, 2Н, J=7.3, Н-2´,6´ Ph), 8.44 (d, 1Н, J=7.9, Н-
11); LC-MS, m/z = 404 [M+1], 406 [M+3]; Anal. calcd. for C22H21N5OS: C, 65.49; Н, 5.75; 
N, 17.36; S, 7.95; Found: C, 65.49; Н, 5.75; N, 17.36; S, 7.95. 
3-Phenyl-6-[(2-piperidine-1-ylethyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (3.2). 
Yield: Method A, 34.3%, Method B, 74.3%; M.p. 150–153°C; IR (cm
−1): 3055, 2955, 2929, 
2850, 2800, 2777, 2754, 2737, 2690, 2667, 2354, 1759, 1729, 1651, 1610, 1583, 1547, 
1496, 1483, 1465, 1453, 1444, 1377, 1339, 1322, 1307, 1277, 1258, 1239, 1212, 1182, 
1165, 1146, 1135, 1124, 1105, 1079, 1042, 1031, 1021, 1000, 986, 957, 940, 909, 892, 
876, 849, 813, 788, 779, 769, 750, 706, 688, 652, 613; 
1H-NMR (500 MHz, DMSO-d6, 
TMS): δ=1.40 (qui, 2Н, -N(CН2CH2)2CН2), 1.53 (qui, 4Н, -N(CН2CH2)2CН2), 2.48 (t, 4Н, -
N(CН2CH2)2CН2), 2.69 (t, 2Н, J=6.8, -S-CH2-CН2-), 3.37 (t, 2Н, J=6.8, -S-CH2-),7.66-7.56 
(m, 4Н, Н-3´, 4´, 5´ Ph, H-10), 7.70 (d, 1Н, J=7.9, Н-8), 7.94 (t, 1Н, J=7.7, Н-9), 8.25 (d, 
2Н,  J=7.3,  2´,  6´  Ph),  8.44  (d,  1Н,  J=7.9,  Н-11); 
13C-NMR (100 MHz):  δ=24.53 
(CН2(CH2CH2)2N-), 26.04 (CН2(CH2CH2)2N-), 28.70 (-S-CH2-), 54.27 (-S-CH2-CH2-), 57.29 
(CН2(CH2CH2)2N-), 118.07 (8), 107.35 (11а), 126.04 (10), 127.87 (11), 129.89 (3´, 5´ Ph), 
129.81 (2´, 6´ Ph), 131.94 (4´ Ph, 11), 132.15 (1´ Ph), 136.02 (9), 144.24 (3), 149.56 (11b), 
151.02  (7а),  155.49  (2),  160.00  (6);  EI-MS,  m/z  (Irel, %) = 170 (5.6), 112 (12.2), 111 
(100.0), 103 (10.5), 99 (12.1), 98 (68.8), 96 (21.3), 83 (9.8), 76 (5.5), 70 (8.5), 69 (7.8), 56 
(8.2), 55 (14.7), 44 (5.6), 42 (8.4), 41 (8.0); LC-MS, m/z = 418 [M+1], 420 [M+3]; Anal. 
calcd. for C23H25N5OS: C, 66.16; Н, 5.55; N, 16.77; S, 7.68; Found: C, 66.18; Н, 5.57; N, 
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6-[(2-Morpholin-4-ylethyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.3). 
Yield: Method A, 36.0%, Method B, 56.0%; M.p. 212–214°C; IR (cm
−1): 3070, 2956, 2922, 
2855, 2800, 2763, 2737, 2700, 2661, 1727, 1662, 1614, 1582, 1551, 1504, 1482, 1468, 
1454, 1376, 1337, 1281, 1258, 1194, 1134, 1115, 1070, 1057, 1041, 1002, 953, 918, 894, 
867, 852, 811, 771, 750, 702, 682, 665, 629, 613; 
1H-NMR (500 MHz, DMSO-d6, TMS): 
δ=1.17  (qui,  4Н,  -N(CН2CH2)2О),  2.75  (t,  2Н,  J=6.8,  -S-CH2-CН2-),  3.09  (qui,  4Н,  -
N(CН2CH2)2О), 3.61 (t, 2Н, J=6.8, -S-CH2-), 7.62-7.54 (m, 4Н, Н-3´, 4´, 5´ Ph, H-10), 7.78 
(d, 1Н, J=7.9, Н-8), 7.97 (t, 1Н, J=7.7, Н-9), 8.33 (d, 2Н, J=7.3, 2´, 6´ Ph), 8.49 (d, 1Н, 
J=7.9, Н-11); LC-MS, m/z = 420 [M+1], 422 [M+3]; Anal. calcd. for C22H21N5O2S: C, 62.99; 
Н, 5.05; N, 16.69; S, 7.64; Found: C, 62.99; Н, 5.05; N, 16.69; S, 7.64. 
3-Phenyl-6-[(2-pyrrolidin-1-ylpropyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.4). 
Yield: Method A, 33.9%; M.p. 146–148°C; IR (cm
−1): 3056, 2998, 2950, 2929, 2865, 2662, 
2563, 2479, 2352, 2318, 1730, 1665, 1586, 1563, 1553, 1504, 1487, 1469, 1443, 1371, 
1341, 1312, 1283, 1266, 1242, 1187, 1156, 1135, 1104, 1080, 1022, 1002, 988, 941, 850, 
812, 779, 751, 689, 668, 654, 623; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.03 (m, 4Н, -
N(CH2)2(CH2)2), 2.33 (m, 2H, -S-CH2-CH2-), 2.99 (m, 4Н, -N(CH2)2(CH2)2), 3.31 (m, 2H, S-
(CH2)2-CH2-), 3.58 (m, 2H, -S-CH2-), 7.60-7.53 (m, 3Н, Н-3´,4´, 5´ Ph), 7.67 (t, 1Н, J=7.7, 
Н-10), 7.86 (d, 1Н, J=7.9, Н-8), 7.96 (t, 1Н, J=7.7, Н-9), 8.34 (d, 2Н, J=7.3, Н-2´,6´ Ph), 
8.56  (d,  1Н,  J=7.9,  Н-11); LC-MS,  m/z  =  418 [M+1], 420 [M+3]; Anal. calcd. for 
C23H23N5OS: C, 66.16; Н, 5.55; N, 16.77; S, 7.68; Found: C, 66.18; Н, 5.58; N, 16.78; S, 
7.69. 
3-Phenyl-6-[(2-piperidine-1-ylpropyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (3.5). 
Yield: Method A, 55.4%; M.p. 151-152°C; IR (cm
−1): 2955, 2930, 2874, 2798, 1730, 1662, 
1587, 1564, 1550, 1504, 1485, 1469, 1455, 1372, 1341, 1309, 1285, 1266, 1244, 1232, 
1180, 1138, 1110, 1078, 1031, 1002, 987, 939, 903, 880, 852, 810, 788, 778, 750, 686, 
654, 623; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.33 (m, 2H, -S-CH2-CH2-), 2.41 (m, 
6Н, -N(CH2)2(CH2)3), 3.45 (m, 2H,-S-(CH2)2-CH2-), 3.57 (m, 4Н, -N(CH2)2(CH2)3), 3.80 (m, 
2H, -S-CH2-), 7.62-7.53 (m, 4Н, Н-3´,4´, 5´ Ph, Н-10), 7.69 (d, 1Н, J=7.9, Н-8), 7.80 (t, 1Н, 
J=7.7, Н-9), 8.35 (d, 2Н, J=7.3, Н-2´,6´ Ph), 8.51 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 432 
[M+1], 434 [M+2]; Anal. calcd. for C24H25N5OS:  C,  66.80;  Н,  5.84;  N,  16.23;  S,  7.43; 
Found: C, 66.82; Н, 5.88; N, 16.23; S, 7.44. 
6-[(2-Morpholin-4-ylpropyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.6). 
Yield: Method A, 50.7%; M.p. 158–160°C; IR (cm
−1): 3055, 2954, 2925, 2853, 1661, 1589, 
1566, 1550, 1502, 1486, 1467, 1442, 1399, 1372, 1340, 1310, 1283, 1264, 1234, 1217, 
1180, 1159, 1135, 1117, 1080, 1031, 1021, 1003, 989, 960, 939, 872, 855, 811, 764, 749, 
706, 685, 667, 651, 632, 613; 
1H-NMR  (500 MHz, DMSO-d6, TMS):  δ=2.31 (qui, 2H, 
J=6.4, -S-CH2-CH2-), 2.54 (m, 4Н, -N(CH2)2(CH2)2О), 3.44 (t, 2H, J=6.4, -S-(CH2)2-CH2-), 
3.59 (m, 4Н, -N(CH2)2(CH2)2О), 3.80 (t, 2H, J=6.4, -S-CH2-), 7.59-7.53 (m, 3Н, Н-3´,4´, 5´ 
Ph), 7.66 (t, 1Н, J=7.7, Н-10), 7.76 (d, 1Н, J=7.9, Н-8), 7.94 (t, 1Н, J=7.7, Н-9), 8.34 (d, 
2Н, J=7.3, Н-2´,6´ Ph), 8.55 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 434 [M+1], 435 [M+2]; 
Anal. calcd. for C23H23N5O2S: C, 63.72; Н, 5.35; N, 16.15; S, 7.40; Found: C, 63.75; Н, 
5.36; N, 16.16; S, 7.41. 
3-Methyl-6-[(2-piperidine-1-ylbutyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (3.7). 
Yield: Method A, 56.9%; M.p. >300°C; IR (cm
−1): 3502, 2916, 2851, 2806, 2768, 1662, 
1625, 1601, 1581, 1558, 1503, 1466, 1429, 1362, 1339, 1284, 1260, 1222, 1157, 1132, 56  G. G. Berest et al.:   
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1105, 1042, 953, 874, 768, 686, 630, 608; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=1.43 
(m,  2Н,  -N(CH2)2(CH2)2CН2), 1.54 (m, 2H, -S-(CH2)2-CH2-),  1.66  (m,  4Н,  -
N(CH2)2(CH2)2CН2), 1.81 (qui, 2H, -S-CH2-CH2-), 1.97 (m, 4Н, -N(CH2)2(CH2)2CН2), 2.34 
(m, 2H, -S-(CH2)3-CH2-), 2.43 (s, 3Н, CН3), 3.29 (qui, 2H, -S-CH2-), 7.64 (t, 1Н, J=7.7, Н-
10), 7.73 (d, 1Н, J=7.9, Н-8), 7.91 (t, 1Н, J=7.7, Н-9), 8.52 (d, 1Н, J=7.9, Н-11); Anal. 
calcd. for C20H25N5OS: C, 62.64; Н, 6.57; N, 18.26; S, 8.36; Found: C, 62.65; Н, 6.58; N, 
18.25; S, 8.38. 
3-Phenyl-6-[(2-piperidine-1-ylbutyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one  (3.8). 
Yield: Method A, 60.3%; M.p. 278–280°C; IR (cm
−1): 3068, 2936, 1665, 1583, 1552, 1502, 
1486, 1468, 1442, 1402, 1371, 1340, 1311, 1283, 1261, 1237, 1181, 1156, 1136, 1103, 
1079, 1031, 1021, 1001, 987, 939, 878, 849, 811, 783, 766, 752, 721, 687, 652, 613; 
1H-
NMR (500 MHz, DMSO-d6, TMS): δ=1.43 (m, 2Н, -N(CH2)2(CH2)2CН2), 1.55 (m, 2H, -S-
(CH2)2-CH2-), 1.69 (m, 4Н, -N(CH2)2(CH2)2CН2), 1.85 (qui, 2H, -S-CH2-CH2-), 2.00 (m, 4Н, 
-N(CH2)2(CH2)2CН2), 2.37 (m, 2H, -S-(CH2)3-CH2-), 3.34 (qui, 2H, -S-CH2-), 7.59-7.52 (m, 
3Н, Н-3´,4´, 5´ Ph), 7.65 (t, 1Н, J=7.7, Н-10), 7.76 (d, 1Н, J=7.9, Н-8), 7.94 (t, 1Н, J=7.7, 
Н-9),  8.31  (d,  2Н,  J=7.3,  Н-2´,6´  Ph),  8.55  (d,  1Н,  J=7.9,  Н-11); Anal. calcd. for 
C25H27N5OS: C, 67.39; Н, 6.11; N, 15.72; S, 7.20; Found: C, 67.36; Н, 6.12; N, 15.73; S, 
7.24. 
3-Methyl-6-[(2-morpholin-4-ylbutyl)thio]-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.9). 
Yield: Method A, 56.9%; M.p. >300°C; IR (cm
−1): 2961, 2911, 2856, 1662, 1625, 1599, 
1582, 1559, 1502, 1466, 1429, 1405, 1361, 1339, 1311, 1284, 1258, 1222, 1208, 1132, 
1042, 1002, 953, 874, 861, 767, 701, 686, 630, 606; 
1H-NMR (500 MHz, DMSO-d6, TMS): 
δ=1.98 (m, 4H, -S-CH2-(CH2)2-), 2.45-2.36 (m, 5Н, CН3, -S-(CH2)3-CH2-), 2.54 (m, 4H, -
N(CH2)2(CH2)2О), 3.31 (m, 2H, -S-CH2-), 3.69-3.57 (m, 4H, -N(CH2)2(CH2)2О), 7.62 (t, 1Н, 
J=7.7, Н-10), 7.73 (d, 1Н, J=7.9, Н-8), 7.92 (t, 1Н, J=7.7, Н-9), 8.53 (d, 1Н, J=7.9, Н-11); 
Anal. calcd. for C19H23N5O2S: C, 59.20; Н, 6.01; N, 18.17; S, 8.32; Found: C, 59.22; Н, 
6.03; N, 18.19; S, 8.33. 
6-[(2-Morpholin-4-ylbutyl)thio]-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.10). 
Yield: Method A, 51.4%; M.p. 278–280°C; IR (cm
−1): 3058, 3005, 2953, 2914, 2852, 1664, 
1587, 1559, 1502, 1486, 1467, 1444, 1370, 1339, 1312, 1283, 1264, 1241, 1229, 1184, 
1162, 1135, 1120, 1104, 1080, 1047, 1032, 1021, 1002, 987, 940, 887, 874, 852, 812, 
786, 752, 706, 688, 666, 653, 613; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.00 (m, 4H, -
S-CH2-(CH2)2-), 2.40-2.33 (m, 2Н, -S-(CH2)3-CH2-), 2.58 (m, 4Н, -N(CH2)2(CH2)2O), 3.35 
(m, 2H, -S-CH2-), 3.69 (m, 4Н, -N(CH2)2(CH2)2О), 7.60-7.52 (m, 3Н, Н-3´,4´, 5´ Ph), 7.66 
(t, 1Н, J=7.7, Н-10), 7.78 (d, 1Н, J=7.9, Н-8), 7.95 (t, 1Н, J=7.7, Н-9), 8.34 (d, 2Н, J=7.3, 
Н-2´,6´ Ph), 8.55 (d, 1Н, J=7.9, Н-11); Anal. calcd. for C24H25N5O2S: C, 64.41; Н, 5.63; N, 
15.65; S, 7.16; Found: C, 64.41; Н, 5.62; N, 15.63; S, 7.18. 
6-{[2-(Dimethylamino)ethyl]thio}-3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.11). 
Yield: Method B, 78.9%, M.p. 144–146°C; IR (cm
−1): 3410, 3354, 3293, 3066, 2977, 2947, 
2917, 2855, 2817, 2762, 2714, 2392, 1666, 1623, 1600, 1581, 1557, 1504, 1481, 1465, 
1428, 1376, 1363, 1346, 1312, 1287, 1262, 1223, 1206, 1161, 1133, 1056, 1043, 1015, 
953, 885, 850, 771, 738, 686, 630, 606; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.31 (s, 
6H, -N(CH3)2, 2.37 (s, 3Н, CH3), 2.79 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.39 (t, 2Н, J=6.9, -S-
CH2-), 7.65 (t, 1Н, J=7.1, Н-10), 7.74 (d, 1Н, J=7.9, Н-8), 7.95 (t, 1Н, J=7.1, Н-9), 8.45 (d,   Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline… 57 
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1Н, J=7.9, Н-11); LC-MS, m/z = 316 [M+1], 318 [M+3]; Anal. calcd. for C15H17N5OS: C, 
57.12; Н, 5.43; N, 22.20; S, 10.17; Found: C, 57.13; Н, 5.43; N, 22.21; S, 10.18. 
6-{[2-(Dimethylamino)ethyl]thio}-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.12). 
Yield: Method B, 92.7%, M.p. 104–106°C; IR (cm
−1): 3058, 2974, 2916, 2849, 2812, 2757, 
2723, 1669, 1658, 1582, 1555, 1503, 1487, 1464, 1456, 1444, 1373, 1337, 1313, 1295, 
1282, 1264, 1236, 1212, 1180, 1160, 1135, 1101, 1078, 1056, 1042, 1019, 1000, 986, 
961, 939, 901, 876, 849, 811, 767, 750, 688, 650, 621; 
1H-NMR (500 MHz, DMSO-d6, 
TMS): δ=2.26 (s, 6Н, -N(CH3)2, 2.67 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.41 (t, 2Н, J=6.9, -S-
CH2-), 7.64-7.59 (m, 3Н, Н-3´,4´,5´ Ph), 7.67 (t, 1Н, J=7.3, Н-10), 7.74 (d, 1Н, J=7.9, Н-8), 
7.96 (t, 1Н, J=7.3, Н-9), 8.26 (d, 2Н, J=7.3, Н-2´,6´ Ph), 8.42 (d, 1Н, J=7.9, Н-11); 
13C-
NMR (100 MHz):  δ=29.44 (-SCH2), 45.38 ((CH3)2N-), 57.64 (-CH2-N-), 118.13 (11a), 
126.03 (8), 126.82 (10), 127.87 (11), 128.85 (3´, 5´ Ph), 129.77 (2´, 6´ Ph), 131.93 (4´ Ph), 
132.15 (1´ Ph), 136.03 (9), 144.24 (3), 149.57 (11b), 151.03 (7a), 155.58 (6), 160.01 (2); 
EI-MS, m/z (Irel, %) = 170 (5.8), 103 (27.3), 102 (13.0), 90 (7.5), 77 (5.0), 76 (17.1), 72 
(68.2), 71 (36.8), 70 (28.9), 63 (8.2), 59 (22.8), 58 (100.0), 56 (30.7), 44 (7.8), 43 (18.1), 
42 (23.7); Anal. calcd. for C20H19N5OS: C, 63.64; Н, 5.07; N, 18.55; S, 8.49; Found: C, 
63.66; Н, 5.07; N, 18.56; S, 8.51. 
6-{[2-(Dimethylamino)ethyl]thio}-3-(4-methylphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-
one (3.13). Yield: Method B, 51.0%, M.p. 130–133°C; IR (cm
−1): 2942, 2917, 2849, 2806, 
2776, 2756, 2728, 1664, 1608, 1584, 1561, 1547, 1513, 1495, 1467, 1372, 1338, 1319, 
1308, 1281, 1267, 1239, 1184, 1161, 1135, 1105, 1068, 1042, 1018, 985, 962, 939, 898, 
830, 769, 712, 700, 684, 625; 
1H-NMR  (500 MHz, DMSO-d6, TMS):  δ=2.28  (s,  6Н,  -
N(CH3)2, 2.40 (s, 3Н, CН3), 2.69 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.39 (t, 2Н, J=6.9, -S-CH2-), 
7.38 (d, 2Н, J=7.7, Н-3,´4´ Ph), 7.65 (t, 1Н, J=7.3, Н-10), 7.72 (d, 1Н, J=7.9, Н=8), 7.94 (t, 
1Н, J=7.3, Н-9), 8.20 (d, 2Н, J=7.7, Н-2´,6´ Ph), 8.45 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 
392 [M+1], 394 [M+3]; Anal. calcd. for C21H21N5OS: C, 64.43; Н, 5.41; N, 17.89; S, 8.19; 
Found: C, 64.43; Н, 5.42; N, 17.81; S, 8.21. 
6-{[2-(Dimethylamino)ethyl]thio}-3-(4-methoxyphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-
one (3.14). Yield: Method B, 68.7%, M.p. 158–162°C; IR (cm
−1): 3013, 2969, 2941, 2824, 
2777, 2705, 1666, 1603, 1580, 1557, 1538, 1513, 1494, 1465, 1418, 1368, 1337, 1318, 
1304, 1264, 1234, 1171, 1138, 1103, 1066, 1051, 1018, 985, 952, 937, 889, 831, 799, 
769, 722, 702, 683, 668, 640, 621; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=2.32 (s, 6Н, -
N(CH3)2, 2.74 (t, 2Н, -S-CH2-CН2-), 3.43 (t, 2Н, -S-CH2-), 3.87 (s, 3Н, CН3O), 7.11 (d, 2Н, 
Н-3,´4´ Ph), 7.77-7.60 (m, 2Н, Н-8, 10), 7.93 (t, 1Н, Н-9), 8.35 (d, 2Н, Н-2´,6´ Ph), 8.47 (d, 
1Н, Н-11); LC-MS, m/z = 408 [M+1], 410 [M+3]; Anal. calcd. for C21H21N5O2S: C, 61.90; Н, 
5.19; N, 17.19; S, 7.87; Found: C, 61.91; Н, 5.19; N, 17.20; S, 7.88. 
6-{[2-(Diethylamino)ethyl]thio}-3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.15). 
Yield: Method B, 58.2%, M.p. 120–122°C; IR (cm
−1): 2968, 2919, 2806, 1663, 1624, 1600, 
1580, 1555, 1502, 1463, 1425, 1374, 1359, 1340, 1312, 1282, 1258, 1218, 1208, 1193, 
1132, 1069, 1042, 1027, 952, 906, 882, 859, 764, 739, 728, 700, 685, 663, 630, 607; 
1H-
NMR (500 MHz, DMSO-d6, TMS): δ=1.04 (t, 6Н, J=6.9, -N(CH2-CH3)2, 2.36 (s, 3Н, CH3), 
2.61 (qui, 4Н, J
2=13.9, J
3=6.2, -N(CH2-CH3)2), 2.81 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.31 (t, 
2Н, J=6.9, -S-CH2-), 7.70-7.61 (m, 2Н, Н-8, 10), 7.95 (t, 1Н, J=7.1, Н-9), 8.43 (d, 1Н, 
J=7.9, Н-11); LC-MS, m/z = 344 [M+1], 346 [M+3]; Anal. calcd. for C17H21N5OS: C, 59.45; 
Н, 6.16; N, 20.39; S, 9.34; Found: C, 59.45; Н, 6.16; N, 20.40; S, 9.36. 58  G. G. Berest et al.:   
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6-{[2-(Diethylamino)ethyl]thio}-3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one (3.16). 
Yield: Method B, 67.8%, M.p. 118–120°C; IR (cm
−1): 3058, 2963, 2926, 2868, 2813, 1659, 
1587, 1556, 1505, 1488, 1469, 1445, 1402, 1372, 1339, 1317, 1284, 1269, 1245, 1206, 
1188, 1164, 1138, 1106, 1070, 1021, 1002, 987, 940, 851, 813, 778, 768, 754, 689, 652, 
623, 613; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=1.05 (t, 6Н, J=7.1, -N(CН2-CH3)2 2.62 
(qui, 4Н, J
2=14.3, J
3=7.1, -N(CH2-CH3)2), 2.83 (t, 2Н, J=7.1, -S-CH2-CН2-), 3.34 (t, 2Н, 
J=7.1, -S-CH2-), 7.63-7.56 (m, 3Н, Н-3´,4´, 5´ Ph), 7.67 (t, 1Н, J
3=7.5, Н-10), 7.73 (d, 1Н, 
J=7.9, Н-8), 7.98 (t, 1Н, J
3=7.1, J
4=1.6, Н-9), 8.27 (d, 2Н, J=6.9, Н-2´, 6´ Ph), 8.48 (d, 1Н, 
J=7.9,  Н-11); 
13C-NMR (100 MHz):  δ=12.56 ((CH3CH2)2N-), 28.89 (-SCH2), 46.91 
((CH3CH2)2N-), 51.36 (-CH2-N-), 118.27 (11a), 126.14 (8), 126.71 (10), 127.90 (11), 
128.91 (3´, 5´ Ph), 129.79 (2´, 6´ Ph), 131.97 (4´ Ph), 132.22 (1´ Ph), 136.08 (9), 144.34 
(3), 149.54 (11b), 151.14 (7a), 155.55 (6), 160.10 (2); LC-MS, m/z = 406 [M+1], 408 [M+3]; 
EI-MS, m/z (Irel, %) = 103 (18,5), 102 (6,0), 100 (17,2), 99 (100,0), 86 (13,1), 76 (9,9), 72 
(6,2), 71 (35,0), 70 (13,5),44 (6,9), 42 (9,1); Anal. calcd. for C22H23N5OS: C, 65.16; Н, 
5.72; N, 17.27; S, 7.91; Found: C, 65.14; Н, 5.72; N, 17.25; S, 7.89. 
6-{[2-(Diethylamino)ethyl]thio}-3-(4-methylphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one 
(3.17). Yield: Method B, 84.0%, M.p. 97–99°C; IR (cm
−1): 3061, 3035, 2962, 2918, 2825, 
2784, 1658, 1611, 1588, 1562, 1546, 1497, 1469, 1371, 1339, 1322, 1305, 1268, 1239, 
1204, 1182, 1162, 1136, 1107, 1084, 1067, 1035, 1020, 989, 960, 940, 875, 853, 831, 
808, 771, 720, 704, 683, 641, 626; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=1.05 (t, 6Н, 
J=7.1, -N(CН2-CH3)2 2.40 (s, 3H, CH3), 2.62 (qui, 4Н, J
2=14.3, J
3=7.1, -N(CH2-CH3)2), 2.83 
(t, 2Н, J=6.9, -S-CH2-CН2-), 3.32 (t, 2Н, J=6.9, -S-CH2-), 7.37 (d, 2Н, J=7.7, Н-3´,4´ Ph), 
7.70-7.63 (m, 2Н, Н-8, 10), 7.95 (t, 1Н, J
3=7.3, Н-9), 8.21 (d, 2Н, J=7.7, Н-2´, 6´ Ph), 8.45 
(d, 1Н, J=7.9, Н-11); LC-MS, m/z = 420 [M+1], 422 [M+3]; Anal. calcd. for C23H25N5OS: C, 
65.85; Н, 6.01; N, 16.69; S, 7.64; Found: C, 65.85; Н, 6.01; N, 16.69; S, 7.64. 
6-{[2-(Diethylamino)ethyl]thio}-3-(4-methoxyphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-
one (3.18). Yield: Method B, 68.8%, M.p. 130–132°C; IR (cm
−1): 2967, 2931, 2873, 2836, 
2801, 1662, 1604, 1586, 1562, 1545, 1513, 1495, 1463, 1421, 1371, 1340, 1320, 1305, 
1286, 1271, 1255, 1239, 1175, 1138, 1108, 1069, 1018, 988, 940, 838, 810, 798, 769, 
722, 702, 684, 637, 624; 
1H-NMR (500 MHz, DMSO-d6, TMS): δ=1.05 (t, 6Н, J=7.1, -
N(CН2-CH3)2), 2.61 (qui, 4Н, J
2=14.3, J
3=7.1, -N(CH2-CH3)2), 2.82 (t, 2Н, J=6.9, -S-CH2-
CН2-), 3.32 (t, 2Н, J=6.9, -S-CH2-), 3.86 (c, 3H, CH3О), 7.12 (d, 2Н, J=8.7, Н-3´,4´ Ph), 
7.71-7.62 (m, 2Н, Н-8, 10), 7.95 (t, 1Н, J
3=7.3, Н-9), 8.34 (d, 2Н, J=8.7, Н-2´, 6´ Ph), 8.44 
(d, 1Н, J=7.9, Н-11); Anal. calcd. for C23H25N5O2S: C, 63.43; Н, 5.79; N, 16.68; S, 7.36; 
Found: C, 63.43; Н, 5.79; N, 16.68; S, 7.36. 
6-{[2-(Diisopropylamino)ethyl]thio}3-methyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one 
(3.19). Yield: Method B, 56.5%, M.p. 96–98°C; IR (cm
−1): 2960, 2921, 2870, 2815, 1664, 
1606, 1581, 1556, 1504, 1465, 1432, 1391, 1363, 1337, 1307, 1284, 1260, 1206, 1158, 
1132, 1116, 1036, 953, 885, 859, 770, 695, 685, 628; 
1H-NMR  (500 MHz, DMSO-d6, 
TMS): δ=1.05 (d, 12Н, J=6.4, -N((CH-(CH3)2)2), 2.35 (s, 3Н, CH3), 2.78 (t, 2Н, J=6.9, -S-
CH2-CН2-), 3.09 (qui, 2Н, J
2=12.5, J
3=6.4, -N((CH-(CH3)2)2, 3.20 (t, 2Н, J=6.9, -S-CH2-), 
7.76-7.61 (m, 2Н, Н-8, 10), 7.94 (t, 1Н, J=7.1, Н-9), 8.42 (d, 1Н, J=7.9, Н-11); LC-MS, m/z 
= 372 [M+1], 374 [M+3]; Anal. calcd. for C19H25N5OS: C, 61.43; Н, 6.78; N, 18.85; S, 8.63; 
Found: C, 61.40; Н, 6.78; N, 18.83; S, 8.60.   Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline… 59 
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6-{[2-(Diisopropylamino)ethyl]thio}3-phenyl-2H-[1,2,4]triazino[2,3-c]quinazolin-2-one 
(3.20). Yield: Method B, 80.7%, M.p. 124–126°C; IR (cm
−1):  3094, 3053, 2964, 2925, 
2870, 2777, 1659, 1591, 1554, 1503, 1485, 1470, 1401, 1378, 1339, 1321, 1311, 1284, 
1262, 1238, 1202, 1184, 1158, 1139, 1114, 1086, 1048, 1029, 1002, 986, 963, 939, 889, 
871, 850, 811, 781, 773, 750, 727, 703, 688, 652, 614; 
1H-NMR (500 MHz, DMSO-d6, 
TMS): δ=1.05 (d, 12Н, J=6.4, -N((CH-(CH3)2)2), 2.82 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.11 (qui, 
2Н, J
2=12.5, J
3=6.4, -N((CH-(CH3)2)2, 3.26 (t, 2Н, J=6.9, -S-CH2-), 7.64-7.56 (m, 3Н, Н-
3´,4´, 5´ Ph), 7.73-7.67 (m, 2Н, Н-8, 10), 7.98 (t, 1Н, J
3=7.1, J
4=1.6, Н-9), 8.29 (d, 2Н, 
J=6.9,  Н-2´,  6´  Ph),  8.49  (d,  1Н,  J=7.9,  Н-11); 
13C-NMR (100 MHz):  δ=21.42 
((CH3CH2CH2)2N-), 32.31 (-SCH2), 44.51 ((CH3CH2CH2)2N-), 48.84 (-CH2-N-), 66.86 
((CH3CH2CH2)2N-), 118.33 (11a), 126.16 (8), 126.58 (10), 127.88 (11), 128.90 (3´, 5´ Ph), 
129.77 (2´, 6´ Ph), 132.00 (4´ Ph), 132.21 (1´ Ph), 136.10 (9), 144.37 (3), 149.42 (11b), 
151.10 (7a), 159.49 (6), 160.08 (2); LC-MS, m/z = 434 [M+1], 436 [M+3]; Anal. calcd. for 
C24H27N5OS: C, 66.49; Н, 6.28; N, 16.15; S, 7.40; Found: C, 66.50; Н, 6.29; N, 16.16; S, 
7.41. 
6-{[2-(Diisopropylamino)ethyl]thio}3-(4-methylphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-2-
one (3.21). Yield: Method B, 53.0%, M.p. 141–144°C; IR (cm
−1): 2958, 2925, 2870, 1665, 
1609, 1589, 1562, 1547, 1498, 1467, 1407, 1394, 1382, 1359, 1339, 1320, 1306, 1279, 
1266, 1237, 1202, 1183, 1158, 1133, 1106, 1070, 1051, 1038,1021, 984, 962, 938, 884, 
867, 854, 833, 771, 756, 712, 699, 685, 679, 640, 625, 603; 
1H-NMR (500 MHz, DMSO-
d6, TMS): δ=1.07 (d, 12Н, J=6.0, -N((CH-(CH3)2)2), 2.41 (s, 3Н, CН3), 2.82 (t, 2Н, J=6.9, -
S-CH2-CН2-), 3.11 (qui, 2Н, N((CH-(CH3)2)2), 3.25 (t, 2Н, J=6.9, -S-CH2-), 7.37 (d, 2Н, 
J=7.7, Н-3´,4´ Ph), 7.70-7.64 (m, 2Н, Н-8, 10), 7.97 (t, 1Н, J=7.3, Н-9), 8.23 (d, 2Н, J=7.7, 
Н-2´, 6´ Ph), 8.47 (d, 1Н, J=7.9, Н-11); EI-MS, m/z (Irel, %) = 438 (2.0), 230 (7.7), 161 
(13.1), 134 (5.6), 133 (5.7), 131 (6.6), 130 (8.8), 129 (18.0), 128 (17.6), 127 (88.8), 104 
(7.4), 103 (13.4), 102 (23.9), 99 (16.6), 98 (29.5), 97 (23.9), 96 (6.3), 95 (9.7), 75 (6.9), 73 
(11.1), 72 (70.8), 71 (49.8), 70 (96.7), 69 (67.5), 68 (19.5), 67 (21.8), 65 (11.6), 64 (8.3), 
63 (10.3), 44 (20.2), 43 (100.0), 42 (38.2), 41 (93.4), 40 (24.4); LC-MS, m/z = 448 [M+1], 
450 [M+3]; Anal. calcd. for C25H29N5OS: C, 67.09; Н, 6.53; N, 15.65; S, 7.16; Found: C, 
67.06; Н, 6.53; N, 15.63; S, 7.14. 
6-{[2-(Diisopropylamino)ethyl]thio}3-(4-methoxyphenyl)-2H-[1,2,4]triazino[2,3-c]quinazolin-
2-one  (3.22). Yield: Method B, 75.5%, M.p. 148–150°C; IR (cm
−1):  3014, 2959, 2929, 
2866, 1665, 1603, 1588, 1563, 1546, 1515, 1500, 1465, 1428, 1392, 1358, 1340, 1319, 
1301, 1283, 1270, 1257, 1238, 1206, 1170, 1157, 1133, 1112, 1051, 1018, 1011, 985, 
963, 938, 884, 838, 810, 799, 754, 723, 699, 681, 634, 623; 
1H-NMR (500 MHz, DMSO-
d6, TMS): δ=1.08 (d, 12Н, J=6.0, -N((CH-(CH3)2)2), 2.83 (t, 2Н, J=6.9, -S-CH2-CН2-), 3.12 
(qui, 2Н, N((CH-(CH3)2)2), 3.25 (t, 2Н, J=6.9, -S-CH2-), 3.86 (s, 3Н, CН3О), 7.12 (d, 2Н, 
J=8.7, Н-3´,4´ Ph), 7.72-7.64 (m, 2Н, Н-8, 10), 7.96 (t, 1Н, J=7.7, Н-9), 8.37 (d, 2Н, J=8.7, 
Н-2´, 6´ Ph), 8.47 (d, 1Н, J=7.9, Н-11); LC-MS, m/z = 464 [M+1], 466 [M+3]; Anal. calcd. 
for C25H29N5O2S: C, 63.77; Н, 6.31; N, 15.11; S, 6.92; Found: C, 63.77; Н, 6.31; N, 15.11; 
S, 6.92. 
Pharmacology 
Bioluminescence inhibition test 
The marine luminescent bacteria Photobacterium leiognathi strain Sh1, isolated from the 
Azov Sea Shrimp, were  used for the bioluminescence analysis [33]. Bacteria were 60  G. G. Berest et al.:   
Sci Pharm. 2012; 80: 37–65 
cultivated in a nutrient environment containing (g/L): pepton – 5, yeast extract – 1.5, meat 
extract  –  1.5, sodium chloride –  30, pH = 7.4. In the acute action test (inhibiting 
luminescence of bacteria), bacteria were diluted with the 3% sodium chloride solution 
down to a concentration of 10
5  cells/mL. 5–50 mg/mL of the studied substances 
suspended in DMSO were mixed with 1 mL of the diluted bacterial suspension. Vials were 
incubated for 10 min at 25°C, then, the intensity of bioluminescence was measured in 
percent (%) relative to the controls, which were prepared without the studied compounds. 
In the chronic action test (inhibiting growth and luminescence of bacteria), growth medium 
was added for potential breeding in a ratio of 1:50 and the mix was incubated for 16–18 h 
at 30°C, whereupon the intensity of bioluminescence was measured the same way as in 
acute action testing. Tetracycline was used as a reference. The bacterial luminescence 
was measured with a Bioluminometer BLM-8801 («Science», Krasnoyarsk, Russia).  
Antimicrobial and antifungal test  
The investigation of antimicrobial and antifungal activity of compounds 2.1–2.8 and 3.1–
3.22 was carried out with the stiff plate agar diffusion method against Escherichia coli, 
Staphylococcus aureus, Mycobacterium luteum, Candida tenuis and Aspergillus niger. The 
amount of microbial cells was 109 c.f.u./mL. Incubation period of bacteria was 24 h at 
35°C, yeast – 48 to 72 h at 28–30°C. Antibiotics vancomicin, oxacillin, nystatin were used 
as standards. The bacterial cultures, standards and the obtained substances were 
streaked across grooves at 5 mg/mL concentration, and then allowed to diffuse in the agar 
nutrient plate. The antimicrobial effect and degree of activity of the tested compounds were 
evaluated by measuring of the inhibition zone diameters (low sensitive: 11–15 mm; 
sensitive: 16–25 mm; highly sensitive >25 mm). All experiments were repeated three 
times. 
Cytotoxic activity against malignant human tumor cells 
Primary anticancer assay was performed at human tumor cell lines panel derived from 
nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, 
National Cancer Institute, Bethesda [24–29]. Tested compounds were added to the culture 
at a single concentration (10
−5 M) and the cultures were incubated for 48 h. End point 
determinations were made with a protein binding dye, sulforhodamine B (SRB). Results for 
each tested compound were reported as the percent of growth of the treated cells when 
compared to the untreated control cells. The percentage growth was evaluated 
spectrophotometrically versus controls not treated with test agents. The cytotoxic and/or 
growth inhibitory effects of the most active selected compounds were tested in vitro 
against the full panel of about 60 human tumor cell lines at 10-fold dilutions of five 
concentrations ranging from 10
−4 to 10
−8 M. A 48-h continuous drug exposure protocol was 
followed and an SRB protein assay was used to estimate cell viability or growth. Using the 
seven absorbance measurements [time zero, (Tz), control growth in the absence of drug 
(C), and test growth in the presence of drug at the five concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentrations levels. Percentage 
growth inhibition was calculated as: 
Ti − Tz
C  −  Tz
×100 
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Ti − Tz
Tz
×100 
for concentrations for which Ti < Tz. 
Three dose response parameters were calculated for each compound. Growth inhibition of 
50% (GI50) was calculated from [(Ti  −  T
z)/(C  −  Tz)]  ×  100 = 50, which is the drug 
concentration resulting in a 50% lower net protein increase in the treated cells (measured 
by SRB staining) as compared to the net protein increase seen in the control cells. The 
drug concentration resulting in total growth inhibition (TGI) was calculated from Ti = Tz. 
The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at 
the end of the drug treatment as compared to that at the beginning) indicating a net loss of 
cells following treatment was calculated from [(Ti  −  Tz)/Tz]  ×100 = -50. Values were 
calculated for each of these three parameters if the level of activity was reached; however, 
if the effect was not reached or was exceeded, the value for that parameter was expressed 
as greater or less than the maximum or minimum concentration tested. The log GI50, log 
TGI, log LC50 were then determined, defined as the mean of the log’s of the individual GI50, 
TGI, LC50 values. The lowest values were obtained 
Conclusion 
In the present paper, 22 new 6-{[ω-(dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-
[1,2,4]triazino[2,3-c]quinazoline-2-ones were described. Six of the synthesized compounds 
were tested for anticancer activity and most of them inhibited the growth of the leukemia, 
melanoma, lung, colon, CNS, ovarian, renal, prostate and breast cancers cell lines. In 
conclusion, these preliminary results allowed identification of the most active compounds 
3.14,  3.16  and  3.18. The latter 6-{[2-(diethylamino)ethyl]thio}-3-(4-methoxyphenyl)-2H-
[1,2,4]triazino[2,3-c]quinazolin-2-one (3.18)  could be prospective antitumor agent (log 
GI50=−5,69 and log TGI=−5.14) with the selective influence on the colon cancer cell lines. 
The obtained results prove the necessity for further investigations to clarify the features 
underlying the antitumor potential of the tested compounds.  
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